SAN DIEGO--(BUSINESS WIRE)--Dec 21, 2022--

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:00 a.m. Pacific Time, followed by a question and answer session.

A live webcast of Acadia’s presentation will be accessible on the company’s website, www.acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Rett syndrome and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter.

View source version on businesswire.com:https://www.businesswire.com/news/home/20221221005543/en/

CONTACT: Media Contact:

Acadia Pharmaceuticals Inc.

Deb Kazenelson

(818) 395-3043

media@acadia-pharm.comInvestor Contact:

Acadia Pharmaceuticals Inc.

Mark Johnson, CFA

(858) 261-2771

ir@acadia-pharm.com 

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: MENTAL HEALTH RESEARCH NEUROLOGY CLINICAL TRIALS BIOTECHNOLOGY HEALTH PHARMACEUTICAL GENERAL HEALTH SCIENCE

SOURCE: Acadia Pharmaceuticals Inc.

Copyright Business Wire 2022.

PUB: 12/21/2022 04:05 PM/DISC: 12/21/2022 04:07 PM

http://www.businesswire.com/news/home/20221221005543/en